Ownership
Private
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Patient Square Capital General Information

Patient Square Capital is a leading healthcare-focused private equity and investment firm. It partners with growth-oriented companies whose products, services, and technologies improve health. The firm's portfolio includes biopharmaceuticals, medical devices, gene therapy developers, healthcare service providers, and enabling technology firms. It manages approximately $11 billion in assets as of September 2024 and has invested in notable companies such as Apollo Therapeutics (biopharma), Alladapt Immunotherapeutics (food allergy therapeutics), CAMP4 Therapeutics (RNA-based therapies), Kriya Therapeutics (gene therapy), Eargo Inc. (hearing device), Hanger Inc. (orthotics/prosthetics), among others.[5][7][3] The firm does not develop drugs or own clinical programs directly but enables innovation through capital deployment. Its subsidiary Enavate Sciences provides capital/strategic support to therapeutic technology companies.[9]

Contact Information

Primary Industry
Investors
Corporate Office
Menlo Park, California
United States

Drug Pipeline

No pipeline data available

For full access to Patient Square Capital's pipeline data

Book a demo

Key Partnerships

Co-investments with major institutional investors/funds on deals such as Apollo Therapeutics Series C ($226M+ led by Patient Square); partnerships are typically at the portfolio company level.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Patient Square Capital Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Patient Square Capital's complete valuation and funding history, request access »

Patient Square Capital Financial Metrics